SUVEN PHARMACEUTICALS
|
SUVEN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 11.80 | 16.16 | 17.83 | 14.23 | 24.91 |
| CEPS(Rs) | 13.94 | 18.04 | 19.36 | 15.48 | 13.38 |
| DPS(Rs) | - | 6.00 | 5.00 | 2.00 | 5.00 |
| Book NAV/Share(Rs) | 80.48 | 68.16 | 59.99 | 46.39 | 66.37 |
| Tax Rate(%) | 25.98 | 26.52 | 32.02 | 22.52 | 21.63 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 38.60 | 42.80 | 44.03 | 43.87 | 46.15 |
| EBIT Margin(%) | 39.29 | 42.68 | 51.18 | 47.47 | 51.28 |
| Pre Tax Margin(%) | 38.59 | 41.72 | 50.53 | 46.32 | 48.51 |
| PAT Margin (%) | 28.56 | 30.66 | 34.35 | 35.89 | 38.02 |
| Cash Profit Margin (%) | 33.75 | 34.24 | 37.31 | 39.02 | 40.84 |
| Performance Ratios | |||||
| ROA(%) | 13.46 | 20.18 | 25.62 | 25.26 | 30.07 |
| ROE(%) | 15.87 | 25.21 | 33.52 | 35.78 | 44.58 |
| ROCE(%) | 21.22 | 33.41 | 45.92 | 40.76 | 50.21 |
| Asset Turnover(x) | 0.47 | 0.66 | 0.75 | 0.70 | 0.79 |
| Sales/Fixed Asset(x) | 1.17 | 1.71 | 2.09 | 1.97 | 2.07 |
| Working Capital/Sales(x) | 0.91 | 1.57 | 1.44 | 2.93 | 4.36 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.86 | 0.58 | 0.48 | 0.51 | 0.48 |
| Receivable days | 42.46 | 47.25 | 46.80 | 39.69 | 57.94 |
| Inventory Days | 94.43 | 81.11 | 66.93 | 67.95 | 72.66 |
| Payable days | 65.90 | 79.70 | 87.45 | 94.44 | 100.95 |
| Valuation Parameters | |||||
| PER(x) | 57.36 | 29.26 | 34.66 | 34.80 | 4.04 |
| PCE(x) | 48.53 | 26.20 | 31.91 | 32.01 | 7.53 |
| Price/Book(x) | 8.41 | 6.93 | 10.30 | 10.68 | 3.04 |
| Yield(%) | - | 1.27 | 0.81 | 0.40 | 2.48 |
| EV/Net Sales(x) | 16.37 | 8.98 | 11.95 | 12.62 | 3.28 |
| EV/Core EBITDA(x) | 36.80 | 19.39 | 23.41 | 27.87 | 6.79 |
| EV/EBIT(x) | 41.66 | 21.02 | 23.34 | 26.58 | 6.40 |
| EV/CE(x) | 8.24 | 6.67 | 9.72 | 9.64 | 2.66 |
| M Cap / Sales | 16.38 | 8.98 | 11.92 | 12.49 | 3.08 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -21.56 | 1.52 | 30.75 | 21.10 | 120.68 |
| Core EBITDA Growth(%) | -24.63 | -7.95 | 47.43 | 13.49 | 134.02 |
| EBIT Growth(%) | -27.84 | -15.32 | 41.05 | 12.11 | 166.14 |
| PAT Growth(%) | -26.99 | -9.37 | 25.24 | 14.30 | 190.10 |
| EPS Growth(%) | -26.99 | -9.37 | 25.24 | -42.85 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.04 | 0.06 | 0.12 | 0.22 |
| Current Ratio(x) | 6.61 | 3.81 | 3.64 | 2.07 | 1.60 |
| Quick Ratio(x) | 5.49 | 2.78 | 2.82 | 1.45 | 1.05 |
| Interest Cover(x) | 55.44 | 44.69 | 79.29 | 41.09 | 18.54 |
| Total Debt/Mcap(x) | - | 0.01 | 0.01 | 0.01 | 0.07 |
Compare Financial Ratios of peers of SUVEN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUVEN PHARMACEUTICALS | ₹29,075.3 Cr | -1.1% | -7.2% | 60.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,603.0 Cr | 2.9% | 6.4% | 48.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹160,862.0 Cr | 0.5% | -2.1% | 59.2% | Stock Analytics | |
| CIPLA | ₹122,810.0 Cr | 2.3% | 1% | 20.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,946.0 Cr | 3.5% | 15.7% | 20.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,377.1 Cr | -0.1% | 2.3% | 41.1% | Stock Analytics | |
SUVEN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN PHARMACEUTICALS | -1.1% |
-7.2% |
60.1% |
| SENSEX | 0.3% |
-2.5% |
10% |
You may also like the below Video Courses
